Bright Minds Biosciences (XCNQ:DRUG) Inventory-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Bright Minds Biosciences's Average Total Inventories for the quarter that ended in Dec. 2023 was C$0.00 Mil. Bright Minds Biosciences's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil.

Bright Minds Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 stayed the same from Sep. 2023 (0.00) to Sep. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Bright Minds Biosciences Inventory-to-Revenue Historical Data

The historical data trend for Bright Minds Biosciences's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Inventory-to-Revenue Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Inventory-to-Revenue

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Bright Minds Biosciences's Inventory-to-Revenue

For the Biotechnology subindustry, Bright Minds Biosciences's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Inventory-to-Revenue falls into.

Bright Minds Biosciences Inventory-to-Revenue Calculation

Bright Minds Biosciences's Inventory-to-Revenue for the fiscal year that ended in Sep. 2023 is calculated as

	Inventory-to-Revenue (A: Sep. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Sep. 2022 )	+	Total Inventories (A: Sep. 2023 ))	/	count )	/	Revenue (A: Sep. 2023 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

Bright Minds Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

Bright Minds Biosciences (XCNQ:DRUG) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Bright Minds Biosciences's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Bright Minds Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0	/	0
	=

Bright Minds Biosciences Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (XCNQ:DRUG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

DRUG:USA

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.